These medtech companies raised the most VC last year

Share

8 (tied). ImmusanT

Cambridge, Mass.
Venture capital raised: $40 million

immusant-logo

ImmusanT raised $40 million in venture capital during its expansion stage of development in the fourth quarter of 2017, according to the MoneyTree Report. This is the company’s third investment sequence and investors include ARCH Venture Partners and Vatera Healthcare Partners.

ImmusanT is working to increase tolerance to gluten in people who have celiac disease. The company is improving diagnosis and treatment by harnessing new discoveries in immunology. ImmusanT is developing a therapeutic vaccine for celiac disease called Nexvax2, as well as a diagnostic and monitoring tool to improve management of the disease.

Next >>

Last Chance to Save for DeviceTalks Boston!

textadimage Early rates for DeviceTalks Boston end August 15th.

Don't miss the chance to save $100 and join top medtech innovators including leaders from Hologic, Google, Gray Matter, TransEnterix, NxStage Medical, Smith & Nephew, HeartFlow, Dynatronics, Johnson & Johnson, Allied Minds, and many more.

View Full Agenda

Register today to save. Use code LASTCALL to save an additional 10%.

Pages: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Speak Your Mind

*